13,785 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Oak Thistle LLC

Oak Thistle LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 13,785 shares of the medical research company's stock, valued at approximately $2,430,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after purchasing an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after buying an additional 712,958 shares during the period. Geode Capital Management LLC raised its position in shares of IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after buying an additional 77,981 shares during the period. Invesco Ltd. raised its position in shares of IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after buying an additional 59,426 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IQV. Evercore ISI lifted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Truist Financial boosted their target price on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. cut their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Cowen reaffirmed a "buy" rating on shares of IQVIA in a research report on Wednesday. Seven analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Price Performance

IQVIA stock traded down $1.65 during mid-day trading on Friday, reaching $199.17. The company had a trading volume of 2,137,777 shares, compared to its average volume of 2,039,105. The stock's 50-day simple moving average is $155.96 and its 200-day simple moving average is $170.53. The company has a market capitalization of $33.86 billion, a P/E ratio of 28.82, a P/E/G ratio of 2.29 and a beta of 1.30. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.64 earnings per share. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.